ProPhase Labs (NASDAQ:PRPH) Lowered to “D+” at TheStreet

TheStreet lowered shares of ProPhase Labs (NASDAQ:PRPH) from a c- rating to a d+ rating in a research report sent to investors on Tuesday, TheStreetRatingsTable reports.

NASDAQ:PRPH remained flat at $$2.07 during trading hours on Tuesday. The company’s stock had a trading volume of 900 shares, compared to its average volume of 9,033. The business has a 50-day moving average of $2.72. ProPhase Labs has a twelve month low of $2.01 and a twelve month high of $4.00.

ProPhase Labs (NASDAQ:PRPH) last posted its quarterly earnings data on Tuesday, May 14th. The company reported ($0.09) earnings per share (EPS) for the quarter. The business had revenue of $2.32 million for the quarter. ProPhase Labs had a negative net margin of 23.26% and a negative return on equity of 14.54%.

An institutional investor recently bought a new position in ProPhase Labs stock. Dimensional Fund Advisors LP purchased a new position in shares of ProPhase Labs Inc (NASDAQ:PRPH) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 10,817 shares of the company’s stock, valued at approximately $34,000. Dimensional Fund Advisors LP owned about 0.09% of ProPhase Labs as of its most recent SEC filing. 4.31% of the stock is owned by institutional investors and hedge funds.

ProPhase Labs Company Profile

ProPhase Labs, Inc engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter(OTC) consumer healthcare products, dietary supplements, and other remedies in the United States. The company offers TK Supplements product line include Legendz XL for sexual health; Triple Edge XL, an energy booster and testosterone support; and Super ProstaFlow+ for prostate and urinary health.

Read More: What does an outperform rating mean?

Receive News & Ratings for ProPhase Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs and related companies with MarketBeat.com's FREE daily email newsletter.